RxDoctor Payments Data

Robert Schuchardt, MD

Family Medicine · Stanley, KSNPI 1346237773

Payments from drug & device makers

$4,132in general payments, 2019–2025

Across 249 payments — averaging $16.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$888
  • Amgen$430
  • Novo Nordisk$422
  • Pfizer$230
  • Lilly USA, LLC$217
  • Teva Pharmaceuticals USA, Inc.$206
  • plus $2K from 25 others

What the payments were for

  • Food & beverage$4,132100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,132 in reported general payments places this provider in the 85th percentile of 1,469 family medicine providers in Kansas.

See all family medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$61,069
Medicare patients
225
Services billed
845

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin25$34,565
MounjaroTirzepatide15$23,631
OzempicSemaglutide19$21,570
JanuviaSitagliptin Phosphate12$14,021
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$7,440
SynthroidLevothyroxine Sodium47$5,079
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$3,498
Rosuvastatin Calcium202$2,906
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C19$2,743
Tamsulosin Hcl70$2,110
Wixela InhubFluticasone Propion/Salmeterol12$1,542
Atorvastatin Calcium277$1,485
Omeprazole121$1,468
Lisinopril202$1,327
Pantoprazole Sodium74$1,323

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$217$23,63115 claims
Novo NordiskOzempic$422$21,57019 claims
MerckJanuvia$31$14,02112 claims
AbbVieSynthroid$888$5,07947 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu$133$2,74319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,469 family medicine providers in Kansas.

Other family medicine in Stanley

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →